Table 1. - Profile of H. pylori-positive patients resistant and not resistant to Clarithromycin (CLA) or Levofloxacin (LVX).
| Not Resistant (n=55) | Resistant to CLA or LVX (n=25) | P value | ||
|---|---|---|---|---|
| Gender | Female (n=41) | 52.7%(29/55) | 48.0% (12/25) | 0.695 |
| Male (n=39) | 47.3%(26/55) | 52.0% (13/25) | ||
| Age | ≤ 45 years (n=34) | 50.9% (28/55) | 24.0% (6/25) | 0.024 |
| > 45 years (n=46) | 49.1% (27/55) | 76.0% (19/25) | ||
| Endoscopic Diagnostic | Normal Mucosa (n=3) | 3.6% (2/55) | 4.0% (1/25) | 0.819 |
| Gastritis (n=54) | 65.5% (36/55) | 72.0% (18/25) | ||
| Gastric Ulcer (n=23) | 30.9% (17/55) | 24.0% (6/25) | ||
| Previous treatment for H. pylori | No (n=70) | 89.1% (49/55) | 84.0% (21/25) | 0.165 |
| ≤ 12 months (n=7) | 5.5% (3/55) | 16.0% (4/25) | ||
| > 12 months (n=3) | 5.5% (3/55) | 0% (0/25) | ||
| Source of water to drink | Public tap (n=68) | 81.8% (45/55) | 92.0% (23/25) | 0.237 |
| Mineral water (n=12) | 18.2% (10/55) | 8.0% (2/25) | ||
| cagA-EPIYA | No (n=50) | 60.0% (33/55) | 68.0% (17/25) | 0.790 |
| ABC (n=19) | 25.5% (14/55) | 20.0% (5/25) | ||
| ABCC/ABCCC (n=11) | 14.5% (8/55) | 12.0% (3/25) |
cagA EPIYA: cytotoxin associated gene A-Glu-Pro-Ile-Tyr-Ala